Brian Sheltons life was ruled by Type 1 diabetes.
When his blood sugar plummeted, he would lose consciousness without warning. He crashed his motorcycle into a wall. He passed out in a customers yard while delivering mail. Following that episode, his supervisor told him to retire, after a quarter century in the Postal Service. He was 57.
His ex-wife, Cindy Shelton, took him into her home in Elyria, Ohio. I was afraid to leave him alone all day, she said.
Early this year, she spotted a call for people with Type 1 diabetes to participate in a clinical trial by Vertex Pharmaceuticals. The company was testing a treatment developed over decades by a scientist who vowed to find a cure after his baby son and then his teenage daughter got the devastating disease.
Mr. Shelton was the first patient. On June 29, he got an infusion of cells, grown from stem cells but just like the insulin-producing pancreas cells his body lacked.
Now his body automatically controls its insulin and blood sugar levels.
Mr. Shelton, now 64, may be the first person cured of the disease with a new treatment that has experts daring to hope that help may be coming for many of the 1.5 million Americans suffering from Type 1 diabetes.
Its a whole new life, Mr. Shelton said. Its like a miracle.
Diabetes experts were astonished but urged caution. The study is continuing and will take five years, involving 17 people with severe cases of Type 1 diabetes. It is not intended as a treatment for the more common Type 2 diabetes.
Weve been looking for something like this to happen literally for decades, said Dr. Irl Hirsch, a diabetes expert at the University of Washington who was not involved in the research. He wants to see the result, not yet published in a peer-reviewed journal, replicated in many more people. He also wants to know if there will be unanticipated adverse effects and if the cells will last for a lifetime or if the treatment would have to be repeated.
But, he said, bottom line, it is an amazing result.
Dr. Peter Butler, a diabetes expert at U.C.L.A. who also was not involved with the research, agreed while offering the same caveats.
It is a remarkable result, Dr. Butler said. To be able to reverse diabetes by giving them back the cells they are missing is comparable to the miracle when insulin was first available 100 years ago.
And it all started with the 30-year quest of a Harvard University biologist, Doug Melton.
Dr. Melton had never thought much about diabetes until 1991 when his 6-month-old baby boy, Sam, began shaking, vomiting and panting.
He was so sick, and the pediatrician didnt know what it was, Dr. Melton said. He and his wife Gail OKeefe rushed their baby to Boston Childrens Hospital. Sams urine was brimming with sugar a sign of diabetes.
The disease, which occurs when the bodys immune system destroys the insulin-secreting islet cells of the pancreas, often starts around age 13 or 14. Unlike the more common and milder Type 2 diabetes, Type 1 is quickly lethal unless patients get injections of insulin. No one spontaneously gets better.
Its a terrible, terrible disease, said Dr. Butler at U.C.L.A.
Patients are at risk of going blind diabetes is the leading cause of blindness in this country. It is also the leading cause of kidney failure. People with Type 1 diabetes are at risk of having their legs amputated and of death in the night because their blood sugar plummets during sleep. Diabetes greatly increases their likelihood of having a heart attack or stroke. It weakens the immune system one of Dr. Butlers fully vaccinated diabetes patients recently died from Covid-19.
Added to the burden of the disease is the high cost of insulin, whose price has risen each year.
The only cure that has ever worked is a pancreas transplant or a transplant of the insulin-producing cell clusters of the pancreas, known as islet cells, from an organ donors pancreas. But a shortage of organs makes such an approach an impossibility for the vast majority with the disease.
Even if we were in utopia, we would never have enough pancreases, said Dr. Ali Naji, a transplant surgeon at the University of Pennsylvania who pioneered islet cell transplants and is now a principal investigator for the trial that treated Mr. Shelton.
For Dr. Melton and Ms. OKeefe, caring for an infant with the disease was terrifying. Ms. OKeefe had to prick Sams fingers and feet to check his blood sugar four times a day. Then she had to inject him with insulin. For a baby that young, insulin was not even sold in the proper dose. His parents had to dilute it.
Gail said to me, If Im doing this you have to figure out this damn disease, Dr. Melton recalled. In time, their daughter Emma, four years older than Sam, would develop the disease too, when she was 14.
Dr. Melton had been studying frog development but abandoned that work, determined to find a cure for diabetes. He turned to embryonic stem cells, which have the potential to become any cell in the body. His goal was to turn them into islet cells to treat patients.
One problem was the source of the cells they came from unused fertilized eggs from a fertility clinic. But in August 2001, President George W. Bush barred using federal money for research with human embryos. Dr. Melton had to sever his stem cell lab from everything else at Harvard. He got private funding from the Howard Hughes Medical Institute, Harvard and philanthropists to set up a completely separate lab with an accountant who kept all its expenses separate, down to the light bulbs.
Over the 20 years it took the lab of 15 or so people to successfully convert stem cells into islet cells, Dr. Melton estimates the project cost about $50 million.
The challenge was to figure out what sequence of chemical messages would turn stem cells into insulin-secreting islet cells. The work involved unraveling normal pancreatic development, figuring out how islets are made in the pancreas and conducting endless experiments to steer embryonic stem cells to becoming islets. It was slow going.
After years when nothing worked, a small team of researchers, including Felicia Pagliuca, a postdoctoral researcher, was in the lab one night in 2014, doing one more experiment.
We werent very optimistic, she said. They had put a dye into the liquid where the stem cells were growing. The liquid would turn blue if the cells made insulin.
Her husband had already called asking when was she coming home. Then she saw a faint blue tinge that got darker and darker. She and the others were ecstatic. For the first time, they had made functioning pancreatic islet cells from embryonic stem cells.
The lab celebrated with a little party and a cake. Then they had bright blue wool caps made for themselves with five circles colored red, yellow, green, blue and purple to represent the stages the stem cells had to pass through to become functioning islet cells. Theyd always hoped for purple but had until then kept getting stuck at green.
The next step for Dr. Melton, knowing hed need more resources to make a drug that could get to market, was starting a company.
His company Semma was founded in 2014, a mix of Sam and Emmas names.
One challenge was to figure out how to grow islet cells in large quantities with a method others could repeat. That took five years.
The company, led by Bastiano Sanna, a cell and gene therapy expert, tested its cells in mice and rats, showing they functioned well and cured diabetes in rodents.
At that point, the next step a clinical trial in patients needed a large, well financed and experienced company with hundreds of employees. Everything had to be done to the exacting standards of the Food and Drug Administration thousands of pages of documents prepared, and clinical trials planned.
Chance intervened. In April 2019, at a meeting at Massachusetts General Hospital, Dr. Melton ran into a former colleague, Dr. David Altshuler, who had been a professor of genetics and medicine at Harvard and the deputy director of the Broad Institute. Over lunch, Dr. Altshuler, who had become the chief scientific officer at Vertex Pharmaceuticals, asked Dr. Melton what was new.
Dr. Melton took out a small glass vial with a bright purple pellet at the bottom.
These are islet cells that we made at Semma, he told Dr. Altshuler.
Vertex focuses on human diseases whose biology is understood. I think there might be an opportunity, Dr. Altshuler told him.
Meetings followed and eight weeks later, Vertex acquired Semma for $950 million. With the acquisition, Dr. Sanna became an executive vice president at Vertex.
The company will not announce a price for its diabetes treatment until it is approved. But it is likely to be expensive. Like other companies, Vertex has enraged patients with high prices for drugs that are difficult and expensive to make.
Vertexs challenge was to make sure the production process worked every time and that the cells would be safe if injected into patients. Employees working under scrupulously sterile conditions monitored vessels of solutions containing nutrients and biochemical signals where stem cells were turning into islet cells.
Less than two years after Semma was acquired, the F.D.A. allowed Vertex to begin a clinical trial with Mr. Shelton as its initial patient.
Like patients who get pancreas transplants, Mr. Shelton has to take drugs that suppress his immune system. He says they cause him no side effects, and he finds them far less onerous or risky than constantly monitoring his blood sugar and taking insulin. He will have to continue taking them to prevent his body from rejecting the infused cells.
But Dr. John Buse, a diabetes expert at the University of North Carolina who has no connection to Vertex, said the immunosuppression gives him pause. We need to carefully evaluate the trade-off between the burdens of diabetes and the potential complications from immunosuppressive medications.
Mr. Sheltons treatment, known as an early phase safety trial, called for careful follow-up and required starting with half the dose that would be used later in the trial, noted Dr. James Markmann, Mr. Sheltons surgeon at Mass General who is working with Vertex on the trial. No one expected the cells to function so well, he said.
The result is so striking, Dr. Markmann said, Its a real leap forward for the field.
Last month, Vertex was ready to reveal the results to Dr. Melton. He did not expect much.
I was prepared to give them a pep talk, he said.
Dr. Melton, normally a calm man, was jittery during what felt like a moment of truth. He had spent decades and all of his passion on this project. By the end of the Vertex teams presentation, a huge smile broke out on his face; the data were for real.
He left Vertex and went home for dinner with Sam, Emma and Ms. OKeefe. When they sat down to eat, Dr. Melton told them the results.
Lets just say there were a lot of tears and hugs.
For Mr. Shelton the moment of truth came a few days after the procedure, when he left the hospital. He measured his blood sugar. It was perfect. He and Ms. Shelton had a meal. His blood sugar remained in the normal range.
Mr. Shelton wept when he saw the measurement.
The only thing I can say is thank you.
Visit link:
A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked.
- Israeli-Based 3D-Printed Lab-Grown Meat Company is Building World's ... - December 27th, 2022
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 13th, 2022
- Global Synthetic Stem Cells Market Is Expected To Reach Around USD 42 Million By 2025 - openPR - October 13th, 2022
- A Look Into the Next Century After 100 Years of Insulin - Cureus - October 13th, 2022
- Grafting and Budding Nursery Crop Plants - North Carolina State University - October 4th, 2022
- Lifting up NC Teachers of the Year and TFA alumni - EdNC - August 22nd, 2022
- Vegan Oysters in Shells? This Startup Just Developed a Prototype to Save the Oceans - VegNews - July 27th, 2022
- How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety and more - KYMA - July 19th, 2022
- Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel iPSC Platform for the Advancement of Next-Generation... - July 3rd, 2022
- W-S organization working on regenerative therapies for 40 organs, tissues - WRAL TechWire - July 3rd, 2022
- BioRestorative Therapies Annou - GuruFocus.com - July 3rd, 2022
- How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety - WYFF4 Greenville - June 13th, 2022
- Pediatric Urologist Dr. Anthony Atala to Receive 2022 Jacobson Innovation Award of the American College of Surgeons for Pioneering Work in... - June 13th, 2022
- The Soybean Plant | NC State Extension Publications - June 4th, 2022
- Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting - Yahoo... - April 6th, 2022
- Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT - Yahoo Finance - November 22nd, 2021
- Cytovia and Cellectis Expand Their TALEN Gene-Edited iNK Partnership to Enable Broader ... - The Bakersfield Californian - November 22nd, 2021
- Study Underway to Evaluate New PD-1/CD3 Antibody in T-cell Lymphoma - Targeted Oncology - October 28th, 2021
- What it means to be the worlds first IVF baby - THE WEEK - August 31st, 2021
- Cellectis Announces Participation in Five Investor Conferences - Yahoo Finance - August 31st, 2021
- Nanodecoy Therapy is an Effective Alternative to Neutralize SARS-CoV-2 Virus - AZoNano - June 23rd, 2021
- 'Nanodecoy' Therapy Binds and Neutralizes SARS-CoV-2 Virus - NC State News - June 23rd, 2021
- Researchers curb local immune response in horses receiving stem cell injury therapy - Horsetalk - February 7th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 7th, 2021
- Invisible pest causes more than $1 billion in crop losses - The Albany Herald - January 13th, 2021
- Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion - Reuters - January 13th, 2021
- Chancellor Harold L. Martin, on His Plan to Safely Open the Nation's Largest HCBU During COVID-19 - TIME - August 23rd, 2020
- Inside the race to ditch formula and grow breast milk in the lab - Wired.co.uk - August 23rd, 2020
- Study finds little evidence to back cord-blood therapy for autism - Spectrum - June 12th, 2020
- Balding men could grow hair back in weeks thanks to 'miracle potion' - Daily Star - May 19th, 2020
- Treatment in clinical trial offers options to woman fighting return of cancer (+ video) - WRAL Tech Wire - February 28th, 2020
- Searching for the 'big break' that could turn stem cells into a weapon against dementia - Genetic Literacy Project - February 28th, 2020
- Why Some COVID-19 Cases Are Worse than Others - The Scientist - February 28th, 2020
- The Future of Bioprinting Research Has a New Road Map - 3DPrint.com - February 14th, 2020
- Top Florida Medical Spa, Amnion of Florida, Partners With Merakris Therapeutics to Advance Their Non-Surgical Treatment Options - Business Wire - December 11th, 2019
- Synthetic Stem Cells Market Is Expecting Revolutionary Growth 2019 with Top Key Players: North Carolina State University (NCSU), Zhengzhou University... - December 6th, 2019
- Clinic pitches unproven treatments to desperate patients, with tips on raising the cash - Seattle Times - December 6th, 2019
- Reviewing vTv Therapeutics Inc. (VTVT)'s and Asterias Biotherapeutics Inc. (:)'s results - MS Wkly - October 27th, 2019
- Reviewing BioCryst Pharmaceuticals Inc. (BCRX)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 27th, 2019
- Global Synthetic Stem Cells Market Estimated to Reach USD 42 Million By 2025 - Daily Market Updates - September 29th, 2019
- Global Synthetic Stem Cells Market to Accumulate Revenues Worth US $42 Million By 2025 - ZMR News Research - September 24th, 2019
- Heal Yourself: How Exosome Therapy Can Repair Age-Damaged Skin - Market Research Finance - September 24th, 2019
- Cesca Therapeutics Inc. (KOOL) Can't Be More Safe. Trades Significantly Higher - Invest Tribune - September 24th, 2019
- Stem Cell Winston Salem North Carolina 27150 - April 5th, 2019
- Clinical Trial for Autism - cordbloodbank.com - March 8th, 2019
- Stem Cell Chapel Hill North Carolina 27514 - February 11th, 2019
- Alumna to compete for Miss America crown on Sunday - UNCSA - February 3rd, 2019
- Stem Cell Therapy Latest Research Charlotte, North Carolina - December 2nd, 2018
- Stem Cell Therapy North Carolina | Regenerative Medicine ... - October 4th, 2018
- Bone Marrow Transplant | Durham, Raleigh, North Carolina ... - July 24th, 2018
- Charlotte, North Carolina - Stem Cells Transplant Institute - July 15th, 2018
- Stem Cell Greensboro North Carolina 27455 - July 15th, 2018
- Spotlights Archive | The University of North Carolina at ... - October 15th, 2017
- Stem Cells in Focus - Blog - Closer Look at Stem Cells - October 10th, 2017
- Avalon Advisors Has Decreased Its Comcast Cmn Class (CMCSA) Position; Neuralstem (CUR)'s Sentiment Is 0 - High Point Observer - September 6th, 2017
- Former basketball star Greg Friel in fight of his life - Fosters - Foster's Daily Democrat - August 15th, 2017
- Lung fibrosis? Stem cell therapy holds promise - The Hindu - The Hindu - August 11th, 2017
- Stem cells may treat lung fibrosis diseases - Futurity: Research News - August 11th, 2017
- CRISPR Edits Genome of Human Embryos - Alzforum - August 11th, 2017
- Cary NC Stem Cell Treatment | Cary North Carolina Cancer ... - November 16th, 2016
- Cato - Research Triangle Park, Durham, North Carolina - August 21st, 2016
- Biotechnology Teacher Resources Online | North Carolina ... - August 19th, 2016
- Stem Cell Research in North Carolina ... Whats Really ... - August 5th, 2016
- JCI - Type 2 alveolar cells are stem cells in adult lung - October 19th, 2015
- Cary North Carolina Stem Cell Research | Cary NC Stem Cell ... - July 2nd, 2015
- Core labs | North Carolina Biotech Center - April 29th, 2015
- Image: Human endothelial cells experiment bound for ISS - February 26th, 2015
- COPD Prognosis Stem Cells Canada, COPD Alternative ... - February 17th, 2015
- Cancer Care Northwest Stem Cell Transplantation - January 10th, 2015
- Dying child approved for new treatment testing - January 2nd, 2015
- New e-Incubator enables real-time imaging of bioengineered tissues in controlled unit - November 5th, 2014
- Committee on Development, Regeneration, and Stem Cell ... - October 31st, 2014
- Local doctor uses stem cells to heal - October 29th, 2014
- Study Offers Fertility Preservation Option to Young Boys with Cancer - October 1st, 2014
- Fayetteville North Carolina Stem Cell Research ... - September 16th, 2014
- Charlotte NC Resources - Stem Cells: Get Facts on Uses ... - September 1st, 2014
- For the first time, researchers isolate adult stem cells ... - August 26th, 2014
- The Man Who Grew Eyes From Scratch - August 26th, 2014
- Carolina Stem Cell Treatment Center | carolina stem ... - August 22nd, 2014
- North Carolina Stem Cell Treatment | Stem Cell Treatments - August 22nd, 2014